3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
2
Tumor-Agnostic
1
Conditions
Neoplasms
1
Neoplasm Metastasis
1
Interventions
pembrolizumab
18
Nivolumab
18
Gemcitabine
9
Ipilimumab
8
Cisplatin
8
Carboplatin
8
Capecitabine
8
Paclitaxel
6
Cetuximab
6
atezolizumab
5
Irinotecan
5
Docetaxel
5
Cyclophosphamide
5
Bevacizumab
5
avelumab
4
Trastuzumab
4
Fluorouracil
4
trametinib
3
spartalizumab
3
Specimen Handling
3
Pemetrexed
3
Leucovorin
3
Everolimus
3
Dexamethasone
3
Biopsy
3
urelumab
2
toripalimab
2
tislelizumab
2
ribociclib
2
repotrectinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
sarilumab
×
Tumor-Agnostic
×
Clear all
NCT04333706
2026-03-10
EMPOWER
University of Southern California
Phase 1/2
Recruiting
65 enrolled